TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25712685

Group type: EXPERIMENTAL
Intervention: Rilotumumab (15 mg/kg) plus epirubicin, cisplatin, and capecitabine (ECX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rilotumumab (7.5 mg/kg) plus ECX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus ECX
Number of subjects: 0
Study: 23052526

Group type: EXPERIMENTAL
Intervention: Nissen 1.5-cm wrap
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Toupet 3-cm wrap
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Nissen 3-cm wrap
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Toupet 1.5-cm wrap
Number of subjects: 153

Group type: COMPARATOR
Intervention: 1.5-cm Toupet
Number of subjects: 153

Group type: COMPARATOR
Intervention: 3-cm Nissen
Number of subjects: 153

Group type: COMPARATOR
Intervention: 1.5-cm wrap
Number of subjects: 153

Group type: COMPARATOR
Intervention: 3-cm wrap
Number of subjects: 153
Study: 21967952

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system containing an antibacterial monomer
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional adhesive system (control)
Number of subjects: 15
Study: 18774439

Group type: EXPERIMENTAL
Intervention: Various therapeutic management options for early PD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17140447

Group type: EXPERIMENTAL
Intervention: Exercise group (prolonged stretching and resistance training)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 180
Study: 12695957

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty using the transgluteal approach
Number of subjects: 209
Study: 11078982

Group type: EXPERIMENTAL
Intervention: GH replacement (2 IU GH/m daily for 4 months)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GH replacement
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8862480

Group type: EXPERIMENTAL
Intervention: Vitamins (vitamin E, 15 mg and vitamin C, 120 mg) and beta-carotene, 6 mg
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Trace elements (zinc, 20 mg, selenium, 100 micrograms)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Vitamins associated with trace elements
Number of subjects: 575

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study: 1799477

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b in a dose of 5 million units (MU) three times per week
Number of subjects: 120

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 120
Study: 6877590

Group type: EXPERIMENTAL
Intervention: Normal mobility
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bed rest for 24 hours
Number of subjects: 120
Study: 30847639

Group type: EXPERIMENTAL
Intervention: Sprint snacks (SS) - 3×20-s 'all out' cycling bouts separated by 1-4-h rest (n=12)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Traditional Sprint Interval Training (SIT) - 3×20-s bouts interspersed with 3-min rest within a 10-min training session (n=16)
Number of subjects: 28
Study: 30592751

Group type: EXPERIMENTAL
Intervention: GDM screening by capillary glucose testing, counselling on nutrition and exercise, follow-up through health center
Number of subjects: 210

Group type: COMPARATOR
Intervention: Routine practice at control facilities
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: GDM screening and management intervention
Number of subjects: 210
Study: 27647873

Group type: EXPERIMENTAL
Intervention: Eluxadoline 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eluxadoline 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eluxadoline 100 mg (intranasal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eluxadoline 200 mg (intranasal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxycodone 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxycodone 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (oral study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (intranasal study)
Number of subjects: 0
Study: 23808615

Group type: EXPERIMENTAL
Intervention: 25 mg amitriptyline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg paroxetine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23000875

Group type: EXPERIMENTAL
Intervention: DHA-phospholipids, melatonin and tryptophan supplementation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 19913360

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cortisol Awakening Response (CAR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Heart rate response to TSST
Number of subjects: 34
Study: 18788648

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 15721000

Group type: EXPERIMENTAL
Intervention: Didactic lecture on acute appendicitis (Group A)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standardized patient interaction (SPI) on acute appendicitis (Group B)
Number of subjects: 126
Study: 12682318

Group type: EXPERIMENTAL
Intervention: L-dopa therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: L-dopa-naive (control group)
Number of subjects: 40
Study: 10373047

Group type: EXPERIMENTAL
Intervention: IFR flight mission (40-min duration)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control session on land
Number of subjects: 35
Study: 9441116

Group type: EXPERIMENTAL
Intervention: Serum 7S collagen concentration in patients with IPF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment in IPF patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation analysis of serum 7S collagen
Number of subjects: 0
Study: 1417133

Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN gamma)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6391270

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1-2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Innovar (fentanyl and droperidol, 2.5-5 ml)
Number of subjects: 0
Study: 31495231

Group type: EXPERIMENTAL
Intervention: Continuous aerobic training
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Intermittent aerobic training
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 87
Study: 30832722

Group type: EXPERIMENTAL
Intervention: 4000 IU/day vitamin D for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 46
Study: 29882616

Group type: EXPERIMENTAL
Intervention: Approach-avoidance training (IG)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo training (CG)
Number of subjects: 232
Study: 27417007

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prasugrel 30 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: IPC
Number of subjects: 300

Group type: COMPARATOR
Intervention: Known predictors including CYP2C19 polymorphisms, age, body mass index, diabetes, and intrinsic platelet reactivity
Number of subjects: 300
Study: 24779961

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD) aiming for 20 E% from carbohydrates
Number of subjects: 59

Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD) aiming for 55-60 E% from carbohydrates
Number of subjects: 59
Study: 22653705

Group type: EXPERIMENTAL
Intervention: Atopaxar (50, 100, or 200 mg daily)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720
Study: 20194812

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 18562985

Group type: EXPERIMENTAL
Intervention: Diaphragm with Acidform
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Diaphragm with placebo gel (HEC)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: HEC applied intravaginally before sex
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Acidform applied intravaginally before sex
Number of subjects: 192

Group type: COMPARATOR
Intervention: Condoms (given to all participants)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Diaphragm (general finding)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Acidform users (with or without diaphragm)
Number of subjects: 192
Study: 15653582

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (balloon angioplasty alone or stenting)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Endovascular treatment with severe stenosis
Number of subjects: 283

Group type: COMPARATOR
Intervention: Endarterectomy patients with > or =70% stenosis
Number of subjects: 283
Study: 12419136

Group type: EXPERIMENTAL
Intervention: 25% metronidazol gel
Number of subjects: 27

Group type: COMPARATOR
Intervention: Carbon fiber tip ultrasonic scaling
Number of subjects: 27
Study: 10482995

Group type: EXPERIMENTAL
Intervention: B cell non‐Hodgkin's lymphomas (NHL)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Low grade NHL (small lymphocytic, follicular, mantle cell lymphoma)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: High grade NHL (diffuse large cell lymphoma)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Malignant NHL B cell tumor growth
Number of subjects: 113
Study: 8156342

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Clinical assessment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Pathological size correlation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Mammographic size correlation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ultrasonographic size correlation
Number of subjects: 35
Study: 3394962

Group type: EXPERIMENTAL
Intervention: Variant of the psoas compartment block (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Classic technique (Group 2)
Number of subjects: 50
Study: 29533167

Group type: EXPERIMENTAL
Intervention: Spanish-language smoking cessation intervention (Libre del cigarillo, por mi familia y por mí: Guía para dejar de fumar)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus group findings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learner verification findings
Number of subjects: 0
Study: 28008557

Group type: EXPERIMENTAL
Intervention: Complex exercise
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional decongestive therapy
Number of subjects: 69
Study: 25044235

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of insulin 0.1U • kg‐1 • h‐1
Number of subjects: 73
Study: 22770485

Group type: COMPARATOR
Intervention: Ambar (FGM) with Filtek Supreme Plus (FSP; 3M ESPE)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fuji II LC (GC America)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ketac Nano (3M ESPE)
Number of subjects: 33
Study: 20519751

Group type: EXPERIMENTAL
Intervention: Video self-instruction (self-learning group)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Traditional classroom instruction (classroom training group)
Number of subjects: 256
Study: 18486414

Group type: EXPERIMENTAL
Intervention: Illustrated format
Number of subjects: 6815

Group type: EXPERIMENTAL
Intervention: Print format
Number of subjects: 6815

Group type: COMPARATOR
Intervention: Interactive voice format
Number of subjects: 6815
Study: 15797159

Group type: EXPERIMENTAL
Intervention: Collective memory training
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Individual memory training
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 139
Study: 12563194

Group type: EXPERIMENTAL
Intervention: Excluder bifurcated endoprosthesis (test, n = 235)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Open surgical repair (control, n = 99)
Number of subjects: 334
Study: 10462097

Group type: EXPERIMENTAL
Intervention: Community reinforcement training intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Popular 12-step self-help group
Number of subjects: 32
Study: 8968177

Group type: EXPERIMENTAL
Intervention: Early tracheal extubation (1-6 hours post-surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Late tracheal extubation (12-22 hours post-surgery)
Number of subjects: 100
Study: 1728908

Group type: COMPARATOR
Intervention: Weight reduction and placebo drug treatment
Number of subjects: 787

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: 25 mg of chlorthalidone
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: 50 mg of atenolol
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Atenolol with weight loss (≥4.5 kg)
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Chlorthalidone with weight loss (≥2.25 kg)
Number of subjects: 787
Study: 6142878

Group type: EXPERIMENTAL
Intervention: Prazosin (alpha 1‐adrenoceptor blockade)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol (beta 1‐adrenoceptor blockade)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (nonselective beta‐adrenoceptor blockade)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31660991

Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg (CAFF300)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TeaCrine® 300 mg (TEA300)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TeaCrine® + Caffeine (COMBO; 150 mg/150 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo 300 mg (PLA)
Number of subjects: 12
Study: 28976114

Group type: EXPERIMENTAL
Intervention: Lipid-based complementary feeding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extreme food insecurity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic constraints
Number of subjects: 0
Study: 27556294

Group type: EXPERIMENTAL
Intervention: Pulsing magnetic field (4mT intensity, 15-Hz frequency, 20min per session, 2 times per week for 2 months, 16 sessions)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (magnetically inactive field, 20min per session, 2 times per week for 2 months, 16 sessions)
Number of subjects: 63
Study: 24760791

Group type: EXPERIMENTAL
Intervention: MRgFUS
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 23031354

Group type: EXPERIMENTAL
Intervention: Low glucose (LG; 2.5 mg/kg per minute)
Number of subjects: 11
Study: 20682017

Group type: EXPERIMENTAL
Intervention: Full-mouth tooth extraction
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 50
Study: 16978741

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 80
Study: 15846265

Group type: EXPERIMENTAL
Intervention: Inhospital cardiac catheterization
Number of subjects: 8286
Study: 11981396

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg oral tablet taken three times per day)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Cinnarizine (150 mg oral capsule taken once daily with dinner)
Number of subjects: 221
Study: 9462525

Group type: EXPERIMENTAL
Intervention: BMC
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: OMC
Number of subjects: 90

Group type: COMPARATOR
Intervention: CMC
Number of subjects: 90
Study: 7781863

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estraderm (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prempak‐C (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HRT (general)
Number of subjects: 0
Study: 1922180

Group type: EXPERIMENTAL
Intervention: Variable frequency, short‐duration trains (VFTs) of electrical pulses
Number of subjects: 12

Group type: COMPARATOR
Intervention: Constant frequency, short‐duration trains (CFTs) of 80, 40 or 20 pps
Number of subjects: 12
Study: 7255508

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Meptazinol (1 mg/kg)
Number of subjects: 12
Study: 31845894

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy (23-month duration after one month of DAPT)
Number of subjects: 2565

Group type: COMPARATOR
Intervention: Reference treatment (12-month DAPT followed by 12 months of aspirin)
Number of subjects: 2565

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 2565

Group type: COMPARATOR
Intervention: Reference treatment
Number of subjects: 2565
Study: 31150789

Group type: EXPERIMENTAL
Intervention: Sesame Oral Immunotherapy (OIT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (observational)
Number of subjects: 60
Study: 28351405

Group type: EXPERIMENTAL
Intervention: Project HEAL intervention (three-workshop cancer educational series)
Number of subjects: 375
Study: 25736340

Group type: EXPERIMENTAL
Intervention: Web-based tailored interactive health communication application (IHCA)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Control website (non-tailored)
Number of subjects: 561
Study: 23962572

Group type: EXPERIMENTAL
Intervention: Music during hysteroscopy
Number of subjects: 356

Group type: COMPARATOR
Intervention: No music during hysteroscopy
Number of subjects: 356
Study: 22848592

Group type: EXPERIMENTAL
Intervention: Pain Monitor based on skin conductance (NFSC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard pain therapy procedures
Number of subjects: 44
Study: 20354543

Group type: EXPERIMENTAL
Intervention: Dose-dense administration of paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of platinum and paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose of pegylated liposomal doxorubicin combined with carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard paclitaxel and carboplatin
Number of subjects: 0
Study: 17523994

Group type: EXPERIMENTAL
Intervention: 10-minute body scan (experimental group n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Natural history passage (control group n = 15)
Number of subjects: 30
Study: 16169422

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin 80 mg/day
Number of subjects: 0
Study: 12471862

Group type: EXPERIMENTAL
Intervention: Arthritis treatment
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Diabetes treatment
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Hypertension treatment
Number of subjects: 593

Group type: COMPARATOR
Intervention: Arthritis control
Number of subjects: 593

Group type: COMPARATOR
Intervention: Diabetes control
Number of subjects: 593

Group type: COMPARATOR
Intervention: Hypertension control
Number of subjects: 593
Study: 9472846

Group type: EXPERIMENTAL
Intervention: Fluoxetine (5-10 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7611312

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty first
Number of subjects: 271

Group type: COMPARATOR
Intervention: Topical medication first
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 271
Study: 2203250

Group type: EXPERIMENTAL
Intervention: High-fat evening meal (41 g fat)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard evening meal (unsupplemented)
Number of subjects: 8
Study: 615785

Group type: EXPERIMENTAL
Intervention: Conventional barium meal
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Double contrast examination
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Endoscopy of the stomach and duodenum
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ordinary X-ray examination
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Supplementary gastroscopy
Number of subjects: 101
Study: 31051508

Group type: EXPERIMENTAL
Intervention: Replacing saturated fatty acids (SFAs) with polyunsaturated fatty acids (PUFAs)
Number of subjects: 99
Study: 26068327

Group type: EXPERIMENTAL
Intervention: 5 h/week of specialist‐taught physical education (PE) from grades 1 to 6
Number of subjects: 86

Group type: COMPARATOR
Intervention: 40 min/week of home‐room teacher‐taught physical education (PE) from grades 1 to 6
Number of subjects: 86
Study: 23075919

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF) counseling up to 6 months
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation and continuation
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF) by 3 months
Number of subjects: 1028
Study: 23084167

Group type: EXPERIMENTAL
Intervention: Emotional intelligence (EI) educational program
Number of subjects: 479

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 479
Study: 19067285

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 5 to 10 ppm
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (oxygen)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 12
Study: 17688822

Group type: EXPERIMENTAL
Intervention: Hand video‐assisted thoracoscopic surgery (HVATS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ivor‐Lewis surgery
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups (HVATS and Ivor‐Lewis)
Number of subjects: 39
Study: 15139874

Group type: EXPERIMENTAL
Intervention: Gambling Related Cognition Scale (GRCS)
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Exploratory factor analysis
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis (CFA)
Number of subjects: 968

Group type: COMPARATOR
Intervention: South Oaks Gambling Screen (SOGS)
Number of subjects: 968

Group type: COMPARATOR
Intervention: Motivation Towards Gambling Scale (MTGS)
Number of subjects: 968

Group type: COMPARATOR
Intervention: Depression Anxiety Stress Scale (DASS-21)
Number of subjects: 968
Study: 11560385

Group type: EXPERIMENTAL
Intervention: Adjustable gastric banding (n = 29)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Vertical banded gastroplasty (n = 30)
Number of subjects: 59